Calyx and Invicro are now Perceptive
Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
Extend the deep and diverse experience of Perceptive’s highly tenured scientific experts to your own clinical development team.
Perceptive’s team of scientific experts are immersed in your therapeutic areas of research and up to date on the evolving trends and regulations that could impact your development program.
They leverage their decades of therapeutically aligned experience to set up your imaging strategy effectively and efficiently, consulting on all aspects of clinical trial imaging from study start up through close out and submission.
Learn more about their expertise and why you can rely on Perceptive’s scientific and medical team to help your development program succeed.
Dr. Zaim has over 25 years of medical imaging experience in both academic and service-related organizations, leading medical and scientific teams as they deliver critical imaging support to the worldwide biopharmaceutical industry. He is a board-certified radiologist with subject matter expertise in imaging biomarkers across a broad array of therapeutic areas.
Dr. Bohnsack is a board-certified radiologist with clinical experience in both EU and USA. For 20+ years he's been reputably positioned at the forefront of oncology imaging advances in the clinical trial industry. He co-authored irRC in 2007 and published irRECIST in 2014 which were subsequently validated in February 2022. Both criteria remain the gold standard in solid-tumor oncology and especially I-O imaging. Oliver earned his M.D. from the University of Essen, Germany, his MBA in Healthcare Management from the University of California and his PhD in Radiology, Radiation Modulation and Reduction in CT at the University of Munich.
Dr. Rohit Sood has contributed as a scientific lead on over 160 imaging clinical trials spanning the entire spectrum, from early to late phase, across multiple therapeutic areas including more than 40 in neurological indications. He has contributed to the science on several Neuro-oncology, Neurodegenerative, Neuropsychiatry and Rare disease clinical trials and has collaborated with our study sponsors to develop criteria for evaluating the eligibility, efficacy, and safety aspects of their studies. As a senior member of several scientific organizations and societies, Dr. Sood is actively engaged in furthering the science in the clinical trial space.
An acknowledged expert in neuroimaging of Alzheimer’s Disease (AD) and other forms of dementia, Prof. Cash brings 20 years of experience to Perceptive. He actively participates on various national and international committees, including DIAN, ADNI, GENFI, and has led the ISTAART Neuroimaging PIA, an organization of over 1700 neuroimaging researchers working in dementia. His research focuses on identifying early signs and characterizing the preclinical stages of dementias and how these changes can better inform clinical trials. He has set up, managed, and analyzed numerous large-scale multi-center studies analyzing biomarkers and brain imaging data.
Dr. Jarecha’s expertise in managing the imaging components of more than 300 oncology and haemato-oncology clinical trials resulted in the submission and approval of more than 20 regional and global oncology indication treatments. Building strong teams in the USA and APAC, he manages the USA, China, and Japan markets’ unique drug development challenges. A board-certified Radiologist, Rudresh served as Co-Chair of a CT Coordinating Committee and CT Volumetry Biomarker Committee in QIBA, RSNA.
Dr. Shao is a Senior Medical Director and Scientific leader of APAC in Perceptive. She has more than 10 years of experiences in medical imaging in clinical research and supported over 100 clinical trials in Oncology which obtained approvals across global regulatory agencies in particular in China. She was the first member of the scientific team of perceptive in Shanghai where she built and led the Scientific and Medical team in China to serve the unique and dynamic requirements of the market across multiple therapeutic areas.
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
